Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11898758 | 0.80 | MAPK1 (0.41) | RAB9ANPC1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL11899073 | 0.78 | HTR2C (0.43) | RAB9ANPC1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL31288016 | 0.78 | PNMT (0.43) | TAAR1LMNACYP3A4 | |
| SCHEMBL15014020 | 0.78 | PNMT (0.43) | TAAR1LMNACYP3A4 | |
| SCHEMBL12419318 | 0.76 | — | — | |
| SCHEMBL4498695 | 0.75 | GRIN1 (0.47) | HTTALDH1A1TAAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8822198 | 0.73 | HIF1A (0.39) | CES1L3MBTL1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL460058 | 0.70 | CALM1 (0.55) | CALM1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15323022 | 0.69 | CALM1 (0.61) | CALM1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2614741 | 0.69 | CALM1 (0.61) | CALM1RAB9ANPC1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | claimed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | claimed |
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20230405080-A1 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-11319315-B2 | Cyclohexyl acid triazole azoles as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2020233618-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 (CN) | 2020-11-26 | — | — | WO | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-9422321-B2 | Pyrimidine nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments | HIGH & NEW TECHNOLOGY RESEARCH CENTER, HENAN ACADEMY OF SCIENCES (CN) | 2016-08-23 | — | — | US | disclosed |
| US-20130303747-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF FOR PREPARING ANTI-TUMOR AND ANTI-VIRUS MEDICAMENTS | HIGH & NEW TECHNOLOGY RESEARCH CENTER, HENAN ACADEMY OF SCIENCES (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303747-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF FOR PREPARING ANTI-TUMOR AND ANTI-VIRUS MEDICAMENTS | TYMP, DUT, NUDT1 | CALM1 3434/4885CES1 1427/4885RAB9A 3120/4885 |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, DGAT2 | CALM1 3054/4885CES1 511/4885RAB9A 3998/4885 |
| US-20230405080-A1 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | UACA, EYA3, ALDH1A2 | CALM1 1519/4885CES1 1338/4885RAB9A 2316/4885 |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | CALM1 4090/4885CES1 119/4885RAB9A 3123/4885 |
| US-11319315-B2 | Cyclohexyl acid triazole azoles as LPA antagonists | LPAR3, LPAR1, LPAR2 | CALM1 1300/4885CES1 276/4885RAB9A 2950/4885 |
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | SMO, SHH, GLI1 | CALM1 774/4885CES1 2486/4885RAB9A 863/4885 |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | CALM1 3031/4885CES1 100/4885RAB9A 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.